5月9日，上海机器人企业傅利叶与上海国际医学（000516）中心举行了"具身智能康复港"揭牌仪式。双 方将围绕具身智能机器人在康复医疗场景的应用标准建设、康复方案共创、科研攻关等展开全面合作， 携手打造国内首个具身智能康复示范基地。(第一财经) ...

| 代码 | 简称 | 今日涨跌幅 | 今日换手率 | 主力资金流量（万 | 主力资金净流入比率 | | --- | --- | --- | --- | --- | --- | | | | （%） | （%） | 元） | （%） | | 300740 | 水羊股 份 | 7.34 | 11.92 | 1365.96 | 2.37 | | 002762 | *ST金 比 | 1.87 | 6.12 | 764.00 | 12.09 | | 002172 | 澳洋健 康 | -1.64 | 5.20 | 490.76 | 3.40 | | 600572 | 康恩贝 | 0.00 | 0.81 | 453.06 | 4.92 | | 002566 | 益盛药 业 | 0.56 | 2.84 | 449.27 | 9.45 | | 000516 | 国际医 学 | -2.10 | 1.02 | 173.25 | 1.49 | | 603139 | 康惠制 | -1.57 | 1.79 | -62.03 | -1.77 | | | 药 | | | | | | 000615 | *ST 美 | 0.63 | 1.59 ...

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of International Medical, indicating a decline in revenue and net profit in the latest quarterly report [1] - As of March 31, 2025, the number of shareholders for International Medical increased to 109,907, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] - The company operates in the health care service sector and has received multiple accolades, including being recognized as one of the top 100 private hospitals in the 2024 benchmark hospital research [1] Group 2 - The latest financial results for the first quarter of 2025 show a revenue of 999.7 million yuan, representing a year-on-year decrease of 14.99%, and a net loss of approximately 106.35 million yuan, a decline of 1.37% year-on-year [1] - The company's current price-to-earnings (P/E) ratio is significantly negative at -45.28, compared to the industry average of 38.00, indicating a poor valuation relative to peers [2] - The market capitalization of International Medical stands at 11.573 billion yuan, with a price-to-book (P/B) ratio of 3.24, which is slightly below the industry median of 2.61 [2]

证券代码：000516 证券简称：国际医学 公告编号：2025-018 西安国际医学投资股份有限公司 关于股份回购进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 西安国际医学投资股份有限公司（以下简称"本公司"或"公司"） 于2024年4月24日召开第十二届董事会第十五次会议，并于2024年5月20 日召开2023年度股东大会，审议通过了《关于回购公司股份方案的议案》 及《关于提请股东大会授权董事会办理本次回购相关事宜的议案》，决 定使用自有资金以集中竞价交易方式回购已发行的人民币普通股（A股） 股票，回购的股份将全部用于注销以减少公司注册资本。本次回购的资 金总额不低于人民币10,000万元（含）且不超过人民币15,000万元（含）， 回购价格不超过人民币9.16元/股（含），具体回购股份的数量以回购 结束时实际回购的股份数量为准。回购期限为自公司股东大会审议通过 本次回购方案之日起12个月内。公司已在中国证券登记结算有限责任公 司深圳分公司开立股份回购专用证券账户。具体内容详见公司分别于 2024年4月26日和5月21日在《中国证券报》《上海证券 ...

5月6日，国际医学今日收盘5.11元，上涨1.39%，最新市净率3.24，总市值115.51亿元。 序号股票简称PE(TTM)PE(静)市净率总市值(元)7国际医学-45.20-45.453.24115.51亿行业平均 38.6644.753.42152.65亿行业中值38.3646.642.7251.49亿1润达医疗-313.36207.372.70114.63亿2何氏眼 科-135.21-117.661.6932.24亿3*ST生物-102.63-99.788.4319.80亿4普瑞眼科-71.97-64.663.0965.86亿5诚达 药业-67.32-115.331.5132.41亿6皓宸医疗-48.55-58.395.7622.01亿8创新医疗-40.51-45.232.4142.50亿9金域 医学-36.51-37.392.07142.54亿10百诚医药-29.56-72.171.4938.07亿11迪安诊断-22.95-25.781.4192.12亿 截至2025年一季报，共有10家机构持仓国际医学，其中其他5家、基金4家、券商1家，合计持股数 75944.78万股，持股市值41.39亿元。 来 ...

2025 年 05 月 02 日 公司研究 评级：买入(首次覆盖) 研究所： 证券分析师： 李明 S0350523090001 lim06@ghzq.com.cn [Table_Title] 2024 年亏损收窄，特色专科建设和精益管理助 力进一步利润改善 ——国际医学（000516）公司动态研究 | 相对沪深 | 表现 300 | | | 2025/04/30 | | --- | --- | --- | --- | --- | | 表现 | | 1M | 3M | 12M | | 国际医学 | | -9.4% | 3.7% | -12.3% | | 沪深 300 | | -3.7% | -1.2% | 4.6% | | 市场数据 | 2025/04/30 | | --- | --- | | 当前价格（元） | 5.04 | | 周价格区间（元） 52 | 4.01-6.77 | | 总市值（百万） | 11,392.33 | | 流通市值（百万） | 11,209.79 | | 总股本（万股） | 226,038.27 | | 流通股本（万股） | 222,416.43 | | 日均成交额（百万） | 90 ...

Core Viewpoint - The 2025 International Medical Innovation Cooperation Forum aims to enhance medical innovation collaboration among countries involved in the Belt and Road Initiative, as well as with ASEAN and SCO member states, following directives from President Xi Jinping [1] Group 1: Forum Objectives - The forum emphasizes the establishment of a new mechanism for international medical innovation cooperation, focusing on innovation sharing [1] - It aims to build a high-level international medical open pilot zone through collaborative efforts [1] - The forum seeks to strengthen exchanges and cooperation in traditional medicine [1] - It promotes the construction of a community for global health and well-being through mutual benefits [1] Group 2: Participation and Theme - Over 400 guests, including leaders and officials from SCO member states, attended the forum [1] - The theme of the forum is "Medical Innovation Sharing, Sustainable Health Development" [1] - The forum released the "2025 International Medical Innovation Cooperation Forum Initiative" [1]

Group 1 - The 2025 International Medical Innovation Cooperation Forum will be held from April 28 to 30 in Fangchenggang City, aiming to deepen medical exchange and cooperation, and promote sustainable development in human health [1] - The forum is co-hosted by the Shanghai Cooperation Organization and the Guangxi Zhuang Autonomous Region government, with multiple activities including an opening ceremony, keynote speeches, exhibitions, sub-forums, and a closing ceremony [1] - Participants will include leaders, health officials, medical experts, and representatives from medical institutions and pharmaceutical companies from SCO member states, observer countries, dialogue partner countries, and ASEAN nations [1] Group 2 - The forum will feature four sub-forums, including a roundtable on international medical security policy exchange, focusing on sharing successful experiences in medical security systems and centralized procurement of pharmaceuticals among SCO member states [2] - A forum on health and industrial innovation will address cutting-edge medical developments, aiming to enhance cooperation in public health and digital economy as part of the global development initiative [2] - A roundtable on the protection and utilization of medicinal resource diversity will discuss international practices and technologies for sustainable use of medicinal plant and animal resources [2] - An international standard seminar on nutritional health foods will aim to deepen mutual recognition of international standards and promote industry cooperation [2]

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected relative increase in stock price of over 20% compared to the benchmark index within the next six months [7][9]. Core Insights - The company reported a steady performance in 2024 with an operating revenue of 4.815 billion yuan, reflecting a growth of 4.28%. However, the net profit attributable to shareholders was a loss of 254 million yuan, although this represented a 31.01% improvement year-on-year [3][10]. - The first quarter of 2025 showed a slight revenue decline of 14.99% compared to the previous quarter, with an operating revenue of 999 million yuan and a net loss of 106 million yuan [3][4]. - The company has seen a steady increase in patient visits, with outpatient visits at high-tech hospitals growing by 0.3% and inpatient admissions by 1.8% in 2024. The central hospital experienced a more significant increase, with outpatient visits up by 19% and inpatient admissions by 15% [4][6]. Financial Performance Summary - In 2024, the gross profit margin was 9.45%, with a slight decrease of 0.10 percentage points. The net profit margin attributable to shareholders improved by 2.70 percentage points to -5.28% [5][10]. - The company is projected to achieve revenues of 4.852 billion yuan in 2025, with a gradual increase to 5.937 billion yuan by 2027. The net profit is expected to improve from a loss of 211 million yuan in 2025 to a profit of 68 million yuan in 2027 [7][10]. - The report highlights effective cost control measures, with a sales expense ratio of 0.76% and a management expense ratio of 11.22% in 2024 [5][10]. Strategic Developments - The company has made significant advancements in its clinical specialties, with several departments receiving provincial and municipal recognition for their clinical excellence. New specialized treatment centers and clinics have been established to enhance service offerings [6][10]. - The implementation of Diagnosis-Related Groups (DRG) has improved treatment efficiency, contributing to a stable growth in patient treatment volumes despite a slight decrease in average treatment costs [4][6].

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected relative increase in stock price of over 20% compared to the benchmark index within the next six months [7][9]. Core Insights - The company reported a steady performance in 2024, with a revenue of 4.815 billion yuan, reflecting a growth of 4.28%. However, the net profit attributable to shareholders was a loss of 254 million yuan, although this represented a 31.01% improvement compared to the previous year [3][10]. - The first quarter of 2025 showed a slight revenue decline of 14.99% year-on-year, with a revenue of 999 million yuan and a net loss of 106 million yuan, indicating ongoing challenges [3][4]. Financial Performance Summary - In 2024, the company achieved a gross margin of 9.45%, with a net profit margin of -5.28%, showing a slight improvement in cost control measures [5]. - The company’s revenue projections for 2025 to 2027 are 4.852 billion yuan, 5.362 billion yuan, and 5.937 billion yuan respectively, with expected net profits gradually improving from a loss of 211 million yuan in 2025 to a profit of 68 million yuan in 2027 [7][10]. Operational Highlights - The company experienced a steady growth in patient volume, with outpatient visits at high-tech hospitals increasing by 0.3% and inpatient admissions by 1.8% in 2024. The central hospital saw a significant increase in outpatient visits by 19% and inpatient admissions by 15% [4]. - The company has made significant advancements in its clinical specialties, with several departments receiving provincial and municipal recognition, enhancing its service offerings [6].